Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

Nikolaus B Wagner; Max M Lenders; Kathrin Kühl; Lydia Reinhardt; Fiona André; Milena Dudda; Natalie Ring; Chiara Ebel; Ramon Stäger; Caroline Zellweger; Roland Lang; Michael Paar; Philipp Gussek; Georg Richtig; Suzan H Stürmer; Susanne Kimeswenger; Angela Oellinger; Andrea Forschner; Ulrike Leiter; Benjamin Weide; Maximilian Gassenmaier; Amadeus Schraag; Bernhard Klumpp; Wolfram Hoetzenecker; Carola Berking; Erika Richtig; Mirjana Ziemer; Johanna Mangana; Patrick Terheyden; Carmen Loquai; Van Anh Nguyen; Christoffer Gebhardt; Friedegund Meier; Stefan Diem; Antonio Cozzio; Lukas Flatz; Martin Röcken; Claus Garbe; Thomas K Eigentler

doi:10.1136/jitc-2021-002350

Citation Tools

PDF

PDF +
Supplementary
Material

XML

Immunotherapy biomarkers

Original research

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Wagner NB, Lenders MM, Kühl K, et al

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

Journal for ImmunoTherapy of Cancer 2021;9:e002350. doi: 10.1136/jitc-2021-002350

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password